Galderma Group N

Research Galderma Group N (GALD) on Bullrun: market cap CHF 43.03B, P/E 88.2, dividend yield 0.2%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CHF 43.03B; P/E is 88.2; dividend yield is 0.2%.

About Galderma Group N

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology.

Frequently asked questions

What is Galderma Group N's market cap?

Galderma Group N's market capitalization is CHF 43.03B.

What is Galderma Group N's P/E ratio?

Galderma Group N's price-to-earnings (P/E) ratio is 88.2.

Does Galderma Group N pay a dividend?

Galderma Group N has a dividend yield of 0.2%.

What does Galderma Group N do?

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology.